LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

30.15 -0.07

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

29.15

Max

30.32

Belangrijke statistieken
By Trading Economics
Inkomsten	2.6M -79M
Verkoop	-60K 15K
EPS	-1.18
Winstmarge	-524,566.667
Werknemers	198
EBITDA	-3M -84M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+87.72% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-200M 2.4B
Vorige openingsprijs	30.22
Vorige sluitingsprijs	30.15

Nieuwssentiment

By Acuity

50%

157 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 mei 2026, 20:36 UTC

Acquisities, Fusies, Overnames

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mei 2026, 23:34 UTC

Marktinformatie

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mei 2026, 23:28 UTC

Marktinformatie

Winsten

Global Forex and Fixed Income Roundup: Market Talk

19 mei 2026, 23:28 UTC

Marktinformatie

Winsten

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mei 2026, 23:10 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 mei 2026, 23:10 UTC

Marktinformatie

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mei 2026, 22:02 UTC

Winsten

ZTO Express (Cayman): Di Xu to Resign From Board

19 mei 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mei 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mei 2026, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mei 2026, 21:37 UTC

Winsten

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mei 2026, 21:31 UTC

Acquisities, Fusies, Overnames

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mei 2026, 21:01 UTC

Winsten

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mei 2026, 20:58 UTC

Winsten

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mei 2026, 20:46 UTC

Populaire aandelen

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mei 2026, 20:43 UTC

Marktinformatie

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mei 2026, 20:34 UTC

Winsten

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries 4Q EPS 5c >JHX

19 mei 2026, 20:32 UTC

Winsten

James Hardie Industries 4Q Sales $1.4B >JHX

19 mei 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mei 2026, 20:18 UTC

Marktinformatie

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mei 2026, 20:13 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

19 mei 2026, 20:13 UTC

Marktinformatie

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mei 2026, 20:03 UTC

Acquisities, Fusies, Overnames

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mei 2026, 20:03 UTC

Acquisities, Fusies, Overnames

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mei 2026, 20:02 UTC

Acquisities, Fusies, Overnames

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mei 2026, 20:02 UTC

Acquisities, Fusies, Overnames

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mei 2026, 19:23 UTC

Marktinformatie

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

87.72% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 56.73 USD 87.72%

Hoogste 90 USD

Laagste 38 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

157 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.